Sequence Review: GLP-1 Weight Loss (2026)

We spent five weeks evaluating Sequence’s GLP-1 weight loss program, with particular attention to their insurance acceptance and clinical approach. Founded in 2022, Sequence is the newest platform on our review list. That newness is both an opportunity and a risk. They’re building something genuinely different from the subscription-box telehealth model, but they’re also still figuring things out.

Here’s what we found.

The Signup Process

Sequence’s onboarding starts with a clinical eligibility screening that takes about 12-15 minutes. The questions are noticeably more medical than what you’ll encounter on consumer-oriented platforms like Hims or Found. Sequence asks detailed questions about your metabolic history, previous weight loss interventions (including bariatric surgery consultations), family history of obesity and diabetes, and current metabolic symptoms.

They also ask for your insurance information upfront. This is a key differentiator. While most telehealth weight loss platforms operate on cash-pay models, Sequence actually tries to run your benefits before you commit. During our signup, we entered our insurance details and Sequence ran a preliminary check within about two business days.

The results of that check determine your path. If your plan is accepted, Sequence can bill your insurance for the clinical visits and potentially for brand-name GLP-1 medications. If your insurance isn’t accepted or doesn’t cover GLP-1s, you can still proceed on a self-pay basis.

After the eligibility screening, you schedule a video consultation with a Sequence physician. And these aren’t general telehealth doctors moonlighting in weight loss. Sequence specifically recruits physicians who specialize in obesity medicine. Many hold board certifications from the American Board of Obesity Medicine (ABOM).

Our initial video consultation ran about 30 minutes. The physician asked detailed follow-up questions about our metabolic history, discussed the evidence base for GLP-1 medications, and outlined a treatment protocol that included specific monitoring milestones. She explained what lab markers she’d be tracking and why. It felt like visiting an obesity specialist’s office, not clicking through a telehealth flow.

From initial signup to receiving medication, the process took about 2-3 weeks. The insurance verification step adds time that cash-pay platforms don’t have. If your insurance requires prior authorization for GLP-1 medications, add another 1-2 weeks. Patience is required.

We’ll be honest: the wait was frustrating. Knowing that patients on Hims or Found could be injecting within a week while we were still in Sequence’s intake pipeline made us question whether the thoroughness was worth the delay. In hindsight, having the insurance piece sorted before starting treatment saved us money and headaches down the line. But in the moment, the slower pace tested our patience.

One thing Sequence handles well during the wait: communication. We received status updates at each stage of the process, from insurance verification to prior authorization to pharmacy fulfillment. We never had to wonder where we stood. Some platforms leave you in a black box after signup, which breeds anxiety. Sequence kept us informed even when the answer was “still waiting on your insurer.”

Medications Offered

Sequence prescribes two GLP-1 medications:

• Semaglutide - Available as compounded medication for self-pay patients, or as brand-name Wegovy for patients with qualifying insurance coverage.
• Tirzepatide - Available as compounded medication for self-pay patients, or as brand-name Mounjaro/Zepbound for insured patients.

The brand-name medication option is significant. If your insurance covers Wegovy or Mounjaro, you could potentially get your medication for just your copay amount, which might be $25-$75/month rather than $200-$400. That’s a dramatic difference.

Sequence’s physicians follow structured clinical protocols for prescribing and dose escalation. They don’t rush patients to higher doses. Our provider laid out a clear 16-week escalation timeline and explained exactly what she’d be looking for at each checkpoint before increasing the dose.

The clinical protocol approach means your treatment follows a structured pathway. Each dose increase is tied to specific criteria: tolerability of the current dose, weight loss trajectory, and lab markers. If you’re not tolerating a dose well, your provider won’t push you to escalate on schedule. If your labs show concerning changes, they’ll adjust the plan. This is how obesity medicine should work. It’s also slower and more conservative than platforms that essentially let patients self-direct their escalation.

Sequence doesn’t offer liraglutide. Their focus is exclusively on semaglutide and tirzepatide, which are the more effective weekly injectables. If your provider believes a daily injection would be more appropriate for your situation, you’d need to look at a platform like Found.

For context on how semaglutide and tirzepatide work, see our GLP-1 medication guide.

Pricing

Sequence’s pricing depends heavily on your insurance situation, which makes quoting exact numbers harder than for cash-pay-only platforms.

With qualifying insurance:

• Sequence membership: $99-$199/month (covers physician visits, monitoring, care coordination)
• Medication: Your insurance copay (potentially $25-$75/month for brand-name GLP-1s)
• Total with insurance: Potentially as low as $124-$274/month

Without insurance (self-pay):

• Sequence membership: $199/month
• Compounded semaglutide: $149-$299/month depending on dose
• Compounded tirzepatide: $249-$399/month depending on dose
• Total self-pay: $348-$598/month

Additional costs:

• Lab work: Sequence orders labs and in many cases, insurance covers them
• Shipping: Free for compounded medications; brand-name medications filled at your pharmacy
• Prior authorization assistance: Included

The with-insurance path is where Sequence really shines. A patient paying $150/month total for physician-led obesity care and brand-name Wegovy is getting extraordinary value compared to someone paying $400/month at a cash-pay platform for compounded semaglutide.

But, and this is a big but, not everyone qualifies. Insurance acceptance depends on your specific plan, your BMI, your state, and whether your insurer covers anti-obesity medications at all. Sequence is transparent about this during the benefits check, but the potential for disappointment is real.

Our Experience

The clinical quality at Sequence is the highest we’ve encountered in telehealth weight loss.

Our physician scheduled a follow-up video consultation two weeks after we started medication to assess tolerability and discuss side effects. She spent 20 minutes on the call, not rushed, not distracted. She adjusted our injection timing based on when we were experiencing the most nausea and explained the pharmacological reasoning behind the change. That level of engagement is unusual.

Sequence also ordered labs at the four-week mark. A1c, fasting insulin, lipid panel, liver enzymes, and basic metabolic panel. Our physician walked us through the results on a follow-up call and used them to confirm that our dose escalation was on track. The lab work was billed to our insurance, so there was no out-of-pocket cost for us.

The monitoring cadence continued throughout our evaluation period. Check-in messages from our care team, weight tracking reminders, and scheduled clinical touchpoints. It felt like being enrolled in a clinical program, not using an app.

Now for the less polished parts.

Sequence’s platform is clearly still being built. The patient portal is functional but sparse. Scheduling is handled through a mix of in-app messaging and email, which feels disjointed. On one occasion, we received conflicting scheduling information: an email said our appointment was at 2pm while the portal showed 3pm. (It was 2pm.) Small issue, but it doesn’t inspire confidence from a company that’s three years old.

The app doesn’t have a native mobile version. You access everything through a mobile-responsive website. It works, but it’s noticeably less smooth than dedicated apps from Hims, Ro, or even Found. Saving your login credentials and navigating between sections requires more taps than it should.

Customer support outside of clinical interactions was average. We had a billing question about how our insurance copay was being calculated and sent a message through the portal. The response took about 36 hours and came via email rather than through the portal where we’d sent it. The answer was accurate and helpful, but the communication channel inconsistency was mildly annoying.

We also noticed that Sequence’s availability varies by state. They’re not yet licensed to operate everywhere, and some states have limited provider availability. If you live in a smaller market, confirm that Sequence can serve your location before investing time in the signup process.

One thing we want to highlight about the clinical interactions: Sequence’s physicians proactively discussed long-term treatment planning from the first consultation. Our provider talked about what success looks like at 6 months, at 12 months, and what tapering off medication could look like if we hit our target weight. She also discussed the realistic possibility that some patients need to stay on medication long-term, which is an honest conversation that some platforms avoid because it might discourage signups.

The monitoring cadence was more frequent than any other platform we’ve tested. Beyond the scheduled video calls, our care team sent brief check-in messages every 10-14 days asking about side effects, appetite changes, and general well-being. The messages were personalized, not automated templates. When we mentioned persistent fatigue during week three, our provider responded within 6 hours with specific advice about meal timing and hydration and asked us to report back in 48 hours. That level of attentiveness stood out.

Pros and Cons

What Sequence Gets Right

Insurance acceptance changes the math. For patients with insurance coverage for anti-obesity medications, Sequence unlocks savings that no cash-pay platform can match. Getting brand-name Wegovy or Mounjaro for a copay is dramatically cheaper than compounded alternatives.

Obesity medicine specialists. Most telehealth weight loss platforms employ general practitioners who prescribe GLP-1s as part of a broader practice. Sequence’s physicians are obesity medicine specialists who understand metabolic health at a deeper level. The quality of our consultations reflected that expertise.

Structured clinical protocols. Dose escalation, lab monitoring, and treatment milestones are built into a clinical framework rather than left to ad-hoc provider judgment. This approach mirrors how the best in-person obesity clinics operate.

Prior authorization assistance. If your insurance requires prior auth for GLP-1 medications, Sequence handles the paperwork. This is a time-consuming, frustrating process that many patients give up on. Having Sequence manage it is a genuine value-add.

Where Sequence Falls Short

Three years old is still very new. Sequence was founded in 2022. They don’t have the track record, patient volume, or operational maturity of platforms that have been running since 2017. That youth shows in the platform’s rough edges, limited geographic availability, and occasional operational hiccups.

Insurance coverage is a gamble. Sequence markets insurance acceptance prominently, but the reality is that many insurance plans still don’t cover anti-obesity medications. If your benefits check comes back negative, the self-pay pricing isn’t particularly competitive compared to established competitors.

The platform needs investment. No native mobile app, inconsistent communication channels, and a bare-bones patient portal make the user experience feel behind the industry standard. The clinical experience is excellent, but everything around it needs work.

Limited availability. Sequence isn’t available in all states, and even in states where they operate, provider availability can be thin. Check availability in your specific location before starting the signup process.

Who It’s Best For

Sequence is the best option for patients whose insurance covers GLP-1 medications. Full stop. If you have a plan that covers Wegovy or Mounjaro, Sequence can potentially save you hundreds of dollars per month compared to every cash-pay alternative.

Beyond insurance, Sequence is ideal for:

• Patients who want obesity-specialized physicians rather than general practitioners
• People with complex metabolic profiles who benefit from lab-based monitoring
• Those who value a clinical, evidence-based approach to weight management
• Patients willing to wait longer for a more thorough onboarding process

Who should look elsewhere: If you want to start treatment quickly, Sequence’s 2-3 week onboarding (potentially longer with prior auth) will test your patience. Patients without insurance coverage for GLP-1s won’t find pricing advantages here. And if you value a polished digital experience, the platform’s current state will feel unfinished compared to more established competitors.

Alternatives to Consider

Depending on your insurance situation, these platforms may serve you better:

• Remedy Meds - Faster onboarding, more polished platform, and clear cash-pay pricing. A better option if your insurance doesn’t cover GLP-1s and you want to get started quickly.
• Calibrate - Also clinical and thorough, with a year-long coaching program included. More established than Sequence but doesn’t accept insurance.
• Ro - Their insurance navigation service can help you explore brand-name coverage without committing to Sequence’s program.

For all options compared side by side, see our best GLP-1 providers for 2026.

FAQ

How do I know if my insurance works with Sequence?

During signup, Sequence runs a preliminary benefits check using your insurance information. This typically takes 1-2 business days. They’ll let you know whether your plan is accepted for clinical visits and whether your insurer covers brand-name GLP-1 medications. You can also call your insurance directly and ask about coverage for anti-obesity medications before starting.

Is Sequence available in my state?

Sequence is expanding but doesn’t yet operate in all 50 states. Check their website for current availability or contact their support team. Even in states where they’re active, provider availability can vary, so confirm that scheduling works for your needs.

How long does prior authorization take?

If your insurance requires prior authorization for GLP-1 medications, the process typically takes 1-3 weeks. Sequence handles the paperwork and follows up with your insurer. Some prior auth requests are approved quickly, while others require appeals. Your Sequence care team keeps you updated throughout.

Can I switch from another provider to Sequence?

Yes. If you’re currently getting GLP-1 medication from another telehealth platform, you can transition to Sequence. You’ll go through their standard onboarding process, including the benefits check and physician consultation. Your new Sequence physician will review your treatment history and continue your medication at the appropriate dose.

What if my insurance denies coverage?

If your insurance doesn’t cover GLP-1 medications, Sequence can prescribe compounded versions on a self-pay basis. Your physician’s treatment doesn’t change. The only difference is the medication source (compounding pharmacy vs. brand-name) and the cost structure (self-pay vs. insurance copay).

The Bottom Line

Sequence is building something genuinely different in the telehealth weight loss space. While most platforms compete on convenience and price, Sequence competes on clinical quality and insurance integration. Their obesity-specialized physicians provide a level of care that rivals in-person specialists, and the potential for insurance-covered brand-name medications makes them the most affordable option for qualifying patients.

The trade-offs are real, though. Sequence is young, the platform is rough, and insurance coverage is never guaranteed. The onboarding process is slower than every competitor on this list. And if your insurance doesn’t come through, the self-pay pricing doesn’t stand out.

If you have insurance that might cover anti-obesity medications, Sequence should be your first call. The potential savings are too significant to ignore. If you’re cash-paying no matter what, you have more established options that deliver a smoother experience.

Check our clinic finder to explore all providers available in your area, including local options that might accept your insurance directly.

One more thing to consider. The telehealth weight loss market is crowded and growing fast. New platforms launch regularly, and existing ones pivot their models. Sequence’s bet on insurance integration positions them well if the trend toward insurance coverage for anti-obesity medications continues. Several major insurers have expanded GLP-1 coverage in the past year, and legislative pressure is building to treat obesity as the chronic medical condition it is.

If that trend holds, Sequence’s model gets stronger over time. More insured patients will be looking for providers who can navigate the insurance process, and Sequence is already built for that. But healthcare policy is unpredictable. If insurance coverage contracts or compounded medications face regulatory changes, the landscape shifts for everyone.

For patients making a decision today, the question is straightforward. Check your insurance. If it covers GLP-1 medications, start with Sequence. The potential savings dwarf anything a cash-pay platform can offer. If your insurance doesn’t cover the medications, weigh Sequence’s clinical quality against competitors who deliver a smoother, more affordable cash-pay experience. There’s no wrong answer, just the one that fits your situation best.